Alopecia Areata Clinical Trial Tracker — Monitor the JAK Inhibitor & Next-Generation Pipeline

A pipeline transformed by JAK inhibitor approvals

Alopecia areata entered a new era in 2022–2023 with the back-to-back FDA approvals of baricitinib (Olumiant) and ritlecitinib (Litfulo) — the first new mechanisms for the disease in decades. Prior to these approvals, management consisted primarily of corticosteroids, off-label methotrexate, and contact immunotherapy, none of which offered durable disease control in moderate-to-severe AA.

The JAK inhibitor approvals created a validated commercial market and accelerated a second wave of development: pediatric label expansion, adolescent-focused JAK inhibitors, next-generation selective JAK3 inhibitors, and entirely novel mechanisms including IL-4/IL-13 pathway inhibition. The current pipeline reflects both the commercial opportunity and unmet needs that remain — particularly in pediatric patients, in severe and refractory forms, and in patients who respond partially or not at all to approved JAK inhibitors.

Key signals that alopecia areata professionals track:

• JAK inhibitor label expansions — baricitinib pediatric (Phase 3), ritlecitinib real-world and post-approval studies
• New JAK inhibitor entrants — deuruxolitinib (Phase 3, not yet approved), upadacitinib real-world safety data
• Novel mechanism Phase 2 data — IL-4/IL-13 (dupilumab), IL-2 pathway (rezpegaldesleukin), other targets
• Pediatric and adolescent populations — distinct regulatory requirements, different hair loss impact, high unmet need
• Long-term safety data — JAK inhibitors carry class-wide safety requirements; real-world registry data is commercially important
• Atopic comorbidity trials — subset of AA patients with concurrent atopic dermatitis, testing combination or shared mechanisms

Active Phase 3 Alopecia Areata Pipeline (2026)

Eight Phase 3 trials are active in alopecia areata, spanning approved drug extensions (pediatric, long-term safety), new entrants (deuruxolitinib), and real-world safety registries following the JAK inhibitor approvals.

Active Phase 2 Alopecia Areata Pipeline (2026)

Five Phase 2 trials are actively running in alopecia areata, testing novel mechanisms beyond JAK inhibition including IL-4/IL-13 blockade (dupilumab), combination approaches, and new small molecules.

The JAK inhibitor wave: baricitinib, ritlecitinib, and deuruxolitinib

Alopecia areata is an autoimmune disease driven by loss of immune privilege in the hair follicle. CD8+ T cells expressing NKG2D engage hair follicle antigens, triggering an IFN-γ dominant immune response that arrests the hair growth cycle. JAK1/2 inhibition (baricitinib) and JAK3/TEC inhibition (ritlecitinib) both dampen this signaling cascade, restoring immune privilege and allowing hair regrowth.

Baricitinib (Olumiant, Eli Lilly/Incyte) — approved, pediatric Phase 3 ongoing

Baricitinib was the first JAK inhibitor approved specifically for alopecia areata, receiving FDA approval in June 2022 at 2 mg and 4 mg daily doses for adults with severe AA (SALT score ≥50). The pivotal BRAVE-AA1 and BRAVE-AA2 trials showed 38–39% of patients achieving SALT ≤20 (substantial hair regrowth) at 36 weeks on 4 mg versus 3–6% on placebo.

Eli Lilly is now running a Phase 3 trial (NCT05723198) in children 6 to under 12 years with alopecia areata — a population with high unmet need where current approved treatments (baricitinib 18+, ritlecitinib 12+) cannot be used. This pediatric extension is a significant label expansion opportunity, as severe AA in young children has profound psychosocial impact and no approved options.

Ritlecitinib (Litfulo, Pfizer) — approved, adolescent label, long-term study active

Ritlecitinib received FDA approval in June 2023 for severe AA in adults and adolescents aged 12 and older — the first treatment approved for the adolescent population. The selectivity profile differs from baricitinib: ritlecitinib irreversibly inhibits JAK3 and TEC family kinases rather than JAK1/2, offering a different tolerability signature (no effect on erythropoietin signaling, potentially lower hemoglobin effect).

Pfizer is running an ongoing long-term Phase 3 safety study (NCT04006457) and multiple real-world characterization studies in the post-approval period. The CorEvitas AA Safety and Effectiveness Registry (NCT05745389) is tracking long-term outcomes across all approved treatments.

Deuruxolitinib — Phase 3, not yet approved

Deuruxolitinib (formerly CTP-543, Concert Pharmaceuticals; now Sun Pharmaceutical Industries) is a selective JAK1/2 inhibitor in Phase 3 development. The two Phase 3 THRIVE-AA trials in adults with severe AA have completed enrollment. Sun Pharma is now running a Phase 3 trial (NCT07133308) in adolescents — setting up a potential approval in the same age range as ritlecitinib if adult data supports an NDA filing.

Deuruxolitinib's differentiation claim rests on selectivity and deuterium chemistry — the deuterium substitution is designed to slow metabolism and allow lower effective doses, potentially with a cleaner tolerability profile. The adult Phase 3 readout will determine whether deuruxolitinib can enter a market already served by two approved agents.

The IL-4 pathway hypothesis: dupilumab in pediatric alopecia areata

A meaningful subset of alopecia areata patients — particularly children — have concurrent atopic dermatitis or other atopic conditions. This overlap has generated a hypothesis: could the Th2 inflammatory component (driven by IL-4 and IL-13) contribute to AA pathogenesis or severity in atopic patients?

Dupilumab (Dupixent, Sanofi/Regeneron) is being tested in a Phase 2 trial (NCT05866562) in pediatric patients with AA and atopic comorbidities at Icahn School of Medicine at Mount Sinai. This is a mechanistically distinct hypothesis from JAK inhibition — rather than broadly dampening IFN-γ signaling, it targets the Th2 axis specifically. A separate trial (NCT07242638) is testing the combination of abrocitinib (JAK1 inhibitor) plus dupilumab in adults with both atopic dermatitis and alopecia areata.

These IL-4 pathway trials are early-stage, but they represent the first systematic exploration of non-JAK mechanisms in AA since the JAK inhibitor approvals. If pediatric AA proves to have a stronger Th2 component than adult AA, dupilumab could become a relevant treatment option for a specific subpopulation.

What DataLookout monitors for alopecia areata

Configure your profile with condition and mechanism keywords to match your specific intelligence needs:

• Condition keywords: "alopecia areata", "alopecia totalis", "alopecia universalis", "patchy alopecia", "severe alopecia"
• Mechanism keywords: "JAK inhibitor", "JAK1", "JAK3", "TEC kinase", "baricitinib", "ritlecitinib", "deuruxolitinib"
• Emerging mechanisms: "IL-4", "IL-13", "dupilumab", "IL-2", "Treg"
• Phase filter: Phase 3 for competitive commercial intelligence; Phase 2 for early pipeline monitoring
• Population filter: Pediatric/adolescent studies for label expansion tracking; adult studies for competitive commercial tracking

Who monitors the alopecia areata clinical trial pipeline

Dermatology pharma BD and competitive intelligence teams

BD teams at companies active in JAK inhibitors (Eli Lilly, Pfizer, AbbVie) and biologics (Sanofi/Regeneron) monitor the AA pipeline for competitive developments, licensing opportunities in novel mechanisms, and pediatric indication expansion signals. The AA market is competitive at the approved-drug level but still early for non-JAK mechanisms — an emerging positive Phase 2 from a novel target can move quickly to in-licensing discussions.

Dermatology analysts and biotech investors

With two approved treatments and a third (deuruxolitinib) in Phase 3, the AA market is maturing. Investors monitoring the pipeline track pediatric label expansion timelines, long-term JAK inhibitor safety data from registries (which bears on prescribing practices), and Phase 2 readouts from novel mechanisms that could represent next-generation differentiation.

Dermatology clinical sites and KOLs

Academic dermatology programs and clinical investigators track new AA trials to identify collaboration and participation opportunities — particularly in pediatric and adolescent programs where specialized site capabilities are required. KOLs advising companies on trial design monitor competitive enrollment dynamics to understand patient availability.

Frequently asked questions

How many alopecia areata clinical trials are currently active?

As of March 2026, approximately 36 alopecia areata trials are active on ClinicalTrials.gov, including 8 Phase 3 and 5 Phase 2 trials. The pipeline has grown substantially since the 2022–2023 FDA approvals of baricitinib and ritlecitinib, which validated the commercial opportunity and accelerated second-wave development including pediatric extensions and novel mechanism exploration.

What JAK inhibitors are approved for alopecia areata?

Two JAK inhibitors are FDA-approved for alopecia areata: baricitinib (Olumiant, Eli Lilly/Incyte) — approved June 2022 for adults with severe AA (SALT ≥50) — and ritlecitinib (Litfulo, Pfizer) — approved June 2023 for adults and adolescents aged 12 and older. Deuruxolitinib (Sun Pharmaceuticals) is in Phase 3 and not yet approved. Upadacitinib (AbbVie) has been studied in AA but is not FDA-approved for this indication.

Is dupilumab being tested for alopecia areata?

Yes. Dupilumab (Dupixent, Sanofi/Regeneron) is being tested in a Phase 2 trial (NCT05866562) in pediatric alopecia areata at Icahn School of Medicine at Mount Sinai. The rationale is the atopic comorbidity common in pediatric AA — dupilumab's IL-4/IL-13 blockade may address a Th2 component in this specific population. A separate trial (NCT07242638) tests abrocitinib combined with dupilumab in adults with both atopic dermatitis and AA.

What is deuruxolitinib and when might it be approved?

Deuruxolitinib is a selective JAK1/2 inhibitor developed by Concert Pharmaceuticals (now Sun Pharmaceutical Industries) using deuterium chemistry to optimize pharmacokinetics. Phase 3 THRIVE-AA trials in adults with severe AA have completed, and a Phase 3 adolescent trial (NCT07133308) is now recruiting. A regulatory submission timeline depends on the adult Phase 3 data package.

How does alopecia areata differ from androgenetic alopecia in terms of clinical trials?

Alopecia areata is an autoimmune condition — the trial pipeline focuses on immune modulators (JAK inhibitors, biologics) targeting T-cell-driven hair follicle destruction. Androgenetic alopecia (pattern hair loss) is driven by androgen signaling and DHT; its trial pipeline focuses on minoxidil, finasteride/dutasteride analogues, and novel topicals. The mechanisms, treatment approaches, and pipelines are entirely distinct.